MedTrace Logo

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

NCT02306811 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2016-12-21

No results posted yet for this study

Summary

Primary Objective:

To assess the long-term safety of vatelizumab in MS patients

Secondary Objective:

To assess the long-term efficacy of vatelizumab

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Vatelizumab

Pharmaceutical form:solution for infusion Route of administration: intravenous

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-04-30
Completion
2016-07-31

Countries

  • United States
  • Canada
  • Poland
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306811 on ClinicalTrials.gov